Abhishek Maiti
UT MD Anderson Cancer Center · UT MD Anderson · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Abhishek Maiti as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:35 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07780565 · Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · not yet recruiting · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome · principal investigator
- Ph1NCT07549464 · Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · not yet recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT06522373 · Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual DiseaseM.D. Anderson Cancer Center · withdrawn · Leukemia · principal investigator
- Ph1NCT06445907 · Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT06285890 · Phase I Study of HC-7366 for Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT05834244 · A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT05519527 · STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisM.D. Anderson Cancer Center · withdrawn · Refractory T Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia (AML) · principal investigator
- Ph2NCT04975919 · Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia · principal investigator
- Ph2NCT03404193 · Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:35 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J · 2021120 citationsRCR 6.8
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.Lancet Haematol · 2019113 citationsRCR 4.0
- Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Blood Cancer J · 202286 citationsRCR 5.7
- Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.Blood Adv · 202177 citationsRCR 4.1
- Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.Lancet Haematol · 202261 citationsRCR 4.0
- Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.Clin Lymphoma Myeloma Leuk · 201949 citationsRCR 1.5
- 47 citationsRCR 10.6
- A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.Acta Haematol · 202243 citationsRCR 2.8